September 2024 in “Clinical Case Reports” This case report highlights a rare presentation of APS-1 in a 28-year-old Pakistani male with cardiovascular and pulmonary symptoms, illustrating the importance of early recognition and multidisciplinary management for improved patient outcomes.
August 2026 in “Quality in Sport” This review discusses evidence that regular physical activity and tailored dietary interventions improve metabolic health in women with PMOS, advocating for personalized lifestyle management in their care, and reports no new clinical results.
July 2026 in “Journal of Ovarian Research” In this review, researchers provided a comprehensive analysis of anti-androgen therapies for polyendocrine metabolic ovarian syndrome (PMOS/PCOS), examining their efficacy and safety while proposing a phenotype-guided management framework and highlighting research gaps, such as long-term cardiovascular safety and predictive biomarkers.
This review examines the potential of Parquetina nigrescens for managing Polyendocrine Metabolic Ovarian Syndrome, emphasizing its pharmacological activities and highlighting its promise as an affordable complementary therapy.
June 2026 in “Biomedical and Therapeutics Letters” This review discusses AMH and ovarian morphology as complementary markers in diagnosing PCOS/PMOS and reports no new clinical results, highlighting the need for a multidomain approach in diagnosis and treatment.